Exelixis' cabozantinib reduces lung and thymic NET progression risk by 81%
PositiveFinancial Markets

Exelixis has announced that its drug cabozantinib significantly reduces the risk of progression in lung and thymic neuroendocrine tumors (NET) by an impressive 81%. This breakthrough is crucial as it offers new hope for patients battling these challenging cancers, potentially improving their quality of life and survival rates. The findings from the clinical trial highlight the importance of innovative treatments in oncology, paving the way for further research and development in cancer therapies.
— Curated by the World Pulse Now AI Editorial System